Adverse Effects and Safety of Etirinotecan Pegol, a Novel Topoisomerase Inhibitor, in Cancer Treatment: A Systematic Review

(E-pub Ahead of Print)

Author(s): Mohamad Samare-Najaf, Ali Samareh, Navid Jamali, Ali Abbasi, Cain C. T. Clark, Majid Jafari Khorchani, Fatemeh Zal*

Journal Name: Current Cancer Therapy Reviews

Become EABM
Become Reviewer
Call for Editor


Background: Due to the increasing prevalence of cancer and the inadequacy of current therapies, the development of novel antitumor pharmaceutics with higher efficacies and lower adverse effects is considered a fundamental tenet of contemporary cancer management. Poly- Ethylene-Glycol (PEG) attachment is a novel pharmaceutical technology to improve the efficacy and safety of chemotherapies. Etirinotecan Pegol (EP), also known as NKTR-102, is the PEGylated form of Irinotecan (CPT-11), which causes cancer cell apoptosis by inhibiting the topoisomerase I enzyme.

Objectives: The present study reviews and evaluates various reports of the EP’s anti-tumor activity in various cancers.

Data Sources: Studies were identified using the Scopus database, with no exclusions. The search terms included Etirinotecan Pegol and NKTR-102, which yielded 125 articles (66 and 59 articles, respectively). In addition, the website was used to find ongoing studies, which resulted in the addition of two studies.

Study Eligibility Criteria: Subsequently, we excluded studies that were published in languages other than English, duplicate articles, and studies with no data.

Results: This systematic review clarifies that EP possesses numerous advantages over many other medications, such as safety, efficacy, increased half-life, increased health-related quality of life, increased overall survival, increased progression-free survival, and decreasing the adverse events in the treatment of various cancers.

Conclusion: Therefore, Etirinotecan Pegol may represent a major contribution to the treatment of various cancers in the future.

Keywords: Cancer, chemotherapy, drug safety, toxicology, clinical trials, topoisomerase inhibitors.

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1573394717666210202103502
Price: $95

Article Metrics

PDF: 38